» Articles » PMID: 31715355

Relationship Between Rheological Properties, in Vitro Release and in Vivo Equivalency of Topical Formulations of Diclofenac

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2019 Nov 13
PMID 31715355
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Determination of bioequivalence remains a challenge in generic topical drug development. To support pharmacokinetic studies, strategies to demonstrate microstructure sameness of the products being compared include in vitro evaluations, such as the comparison of rheological properties, droplet size and in vitro release rates. Nevertheless, defining the appropriate acceptance range to consider equivalence between test and reference formulation is complex. To shed more light into this issue, in vitro release and rheological properties were compared to in vivo bioequivalence data (systemic blood measurements within a clinical trial) after topical application of a single dose. Test and reference formulations of diclofenac diethylamine emulgels were evaluated. While the test formulation met the requirements for equivalence in both the in vivo bioequivalence and in vitro release study, the rheological properties were considered equivalent depending on the criteria used. The 90% confidence interval of the ratios between geometric mean values of both formulations were within the limits of 75-133%, but outside the 90-111% limit under discussion in the scientific community. Altogether these data indicate that differences beyond ±10% between rheological parameters of test and reference formulation might not translate into meaningful release nor bioavailability divergence.

Citing Articles

Evaluation of Physicochemical, Microstructure Parameters (Q3) and Performance Attributes of Commercial Ketoprofen Gels.

Iskin S, Kahraman E, Gungor S AAPS PharmSciTech. 2025; 26(2):53.

PMID: 39904831 DOI: 10.1208/s12249-025-03044-4.


Impact of Time on Parameters for Assessing the Microstructure Equivalence of Topical Products: Diclofenac 1% Emulsion as a Case Study.

Manez-Asensi A, Hernandez M, Mangas-Sanjuan V, Salvador A, Merino-Sanjuan M, Merino V Pharmaceutics. 2024; 16(6).

PMID: 38931871 PMC: 11207613. DOI: 10.3390/pharmaceutics16060749.


Sustainable Alternatives to Petroleum-Derived Excipients in Pharmaceutical Oil-in-Water Creams.

Gates D, Badruddoza A, Zahid M, Yeoh T, Shah J, Walsh T AAPS PharmSciTech. 2024; 25(4):68.

PMID: 38538866 DOI: 10.1208/s12249-024-02784-z.


Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union.

Garcia-Arieta A, Gordon J, Gwaza L, Merino V, Mangas-Sanjuan V Pharmaceutics. 2023; 15(2).

PMID: 36839924 PMC: 9961670. DOI: 10.3390/pharmaceutics15020601.


Phenytoin-loaded bioactive nanoparticles for the treatment of diabetic pressure ulcers: formulation and in vitro/in vivo evaluation.

Sheir M, Nasra M, Abdallah O Drug Deliv Transl Res. 2022; 12(12):2936-2949.

PMID: 35403947 PMC: 9636106. DOI: 10.1007/s13346-022-01156-z.